PMID- 12211407
OWN - NLM
STAT- MEDLINE
DCOM- 20030318
LR  - 20151119
IS  - 1472-4472 (Print)
IS  - 1472-4472 (Linking)
VI  - 3
IP  - 8
DP  - 2002 Aug
TI  - Anti-IgE therapy of asthma.
PG  - 1157-60
AB  - There is a strong association between serum levels of immunoglobulin E (IgE) and 
      asthma development. Allergen binds to IgE on basophils and mast cells, leading to 
      cell degranulation and release of inflammatory mediators. A humanized antibody to 
      IgE that reduces circulating free IgE, omalizumab (Genentech Inc/Novartis 
      AG/Tanox Inc), inhibits the early- and late-phase response to allergen. In 
      clinical trials of moderate-to-severe asthma, omalizumab allowed a reduction in 
      oral and inhaled corticosteroids while improving peakflows and reducing 
      exacerbations, particularly in patients at high risk of serious asthma-related 
      morbidity. Omalizumab is a useful addition to the treatment armamentarium for 
      patients with moderate-to-severe asthma.
FAU - Chung, K Fan
AU  - Chung KF
AD  - National Heart & Lung Institute, London, UK. f.chung@ic.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (Allergens)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, Fc)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/pharmacology
MH  - Anti-Asthmatic Agents/pharmacokinetics/*pharmacology/therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Child
MH  - Humans
MH  - Immunoglobulin E/*physiology
MH  - Omalizumab
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Fc/drug effects
MH  - Rhinitis, Allergic, Seasonal/drug therapy
RF  - 30
EDAT- 2002/09/05 10:00
MHDA- 2003/03/19 04:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2003/03/19 04:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2002 Aug;3(8):1157-60.